Slow vs standard up-titration of paroxetine in the treatment of panic disorder: A prospective randomized trial

Psychiatry and Clinical Neurosciences

Volumn 64, Issue 6, 2010, Pages 612-619

  Buoli, Massimiliano ^a   Dell'Osso, Bernardo ^a   Bosi, Monica Francesca ^b   Altamura, Carlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

effectiveness; panic disorder; titration; tolerability

Indexed keywords

PAROXETINE;

ADULT; AGED; AGORAPHOBIA; ARTICLE; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PANIC; PROSPECTIVE STUDY; RANDOMIZATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 78649669312     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2010.02136.x     Document Type: Article

References (38)

1. Kinley DJ, Cox BJ, Clara I, Goodwin RD, Sareen J,. Panic attacks and their relation to psychological and physical functioning in Canadians: results from a nationally representative sample. Can. J. Psychiatry 2009; 54: 113-122.
2. Alonso J, Angermeyer MC, Bernert S, et al. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand. 2004; 420: 38-46.
3. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE,. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005; 62: 617-627. (Pubitemid 40973437)
4. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE,. Lifetime prevalence and age of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005; 62: 593-602. (Pubitemid 40973434)
5. Altamura AC, Santini A, Salvadori D, Mundo E,. Duration of untreated illness in panic disorder: a poor outcome risk factor? Neuropsychiatr. Dis. Treat. 2005; 1: 345-347.
6. Diaconu G, Turecki G,. Panic disorder and suicidality: is comorbidity with depression the key? J. Affect. Disord. 2007; 104: 203-209.
7. Zvolensky MJ, Bernstein A, Marshall EC, Feldner MT,. Panic attacks, panic disorder, and agoraphobia: associations with substance use, abuse, and dependence. Curr. Psychiatry Rep. 2006; 8: 279-285.
8. Wittchen HU, Jacobi F,. Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur. Neuropsychopharmacol. 2005; 15: 357-376.
9. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ,. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines to the pharmacological treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorder. World J. Biol. Psychiatry 2002; 3: 171-199.
10. Baldwin DS, Anderson IM, Nutt DJ, et al.; British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 2005; 9: 567-596.
11. Pull CB, Damsa C,. Pharmacotherapy of panic disorder. Neuropsychiatr. Dis. Treat. 2008; 4: 779-795.
12. Fang SY, Chen CY, Chang IS, Wu EC, Chang CM, Lin KM,. Predictors of the incidence and discontinuation of long-term use of benzodiazepines: a population-based study. Drug Alcohol Depend. 2009; 104: 140-146.
13. Hoffman EJ, Mathew SJ,. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt. Sinai J. Med. 2008; 75: 248-262.
14. Bakker A, Van Balkom AJ, Spinhoven P,. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr. Scand. 2002; 106: 163-167.
15. Stein MB, Goin MK, Pollack MH, et al. Practice Guideline for the Treatment of Patients with Panic Disorder, 2nd edn. American Psychiatric Press, Washington, DC, 2009.
16. Sheehan DV, Burnham DB, Iyengar MK, Perera P, Paxil CR Panic Disorder Study Group. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J. Clin. Psychiatry 2005; 66: 34-40.
17. Gunasekara NS, Noble S, Benfield P,. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 2008; 55: 85-120.
18. Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M,. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry 2004; 4: 16-21.
19. Seguí J, Márquez M, Canet J, García L,. Causes of failure in psychopharmacological treatment of anxiety disorder. Actas Esp. Psiquiatr. 1999; 27: 250-258.
20. Batelaan NM, De Graaf R, Penninx BW, Van Balkom AJ, Vollebergh WA, Beekman AT,. The 2-year prognosis of panic episodes in the general population. Psychol. Med. 2009; 29: 1-11.
21. Toni C, Perugi G, Frare F, Mata B, Akiskal HS,. Spontaneous treatment discontinuation in panic disorder patients treated with antidepressants. Acta Psychiatr. Scand. 2004; 110: 130-137.
22. Eaddy M, Sheehan D, Sarnes M, Regan T, Mauch R,. SSRI utilization patterns and the economic consequences of early discontinuation. 2004. Poster presented at 157th annual Meeting of the American psychiatric Association, New York, NY.
23. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med. Care 1995; 33: 67-74.
24. Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br. J. Psychiatry 2009; 194: 483-490.
25. Stein MB,. Anxiety disorders: somatic treatment. In:, Sadock BS, Sadock VA, (eds). Kaplan and Sadock's Comprehensive Textbook of Psychiatry. Lippincott, Williams & Wilkins, Philadelphia, PA, 2005; 1906-1914.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). American Psychiatric Press, Washington, DC, 1994.
27. First MB, Spitzer RL, Gibbon M, Williams JBM,. Structured Clinical Interview Diagnostic (SCID) for DSM-IV Axis I Disorders-Clinician Version. American Psychiatric Press, Washington, DC, 1997.
28. Sheehan DV,. Sheehan Anxiety and Panic Attack Scales. Kalamazoo, Upjohn, MI, 1983.
29. Guy W,. DOTES: Dosage Record and Treatment Emergent Symptom Scale, in ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, Bethesda, MD, 1976.
30. Ramnerö J, Ost LG,. Panic and avoidance in panic disorder with agoraphobia: clinical relevance of change in different aspects of the disorder. J. Behav. Ther. Exp. Psychiatry 2007; 38: 29-39.
31. Sardinha A, Freire RC, Zin WA, Nardi AE,. Respiratory manifestations of panic disorder: causes, consequencesand therapeutic implications. J. Bras. Pneumol. 2009; 35: 698-708.
32. Craske MG, Roy-Byrne PP, Stein MB, Sullivan G, Sherbourne C, Bystritsky A,. Treatment for anxiety disorders: efficacy to effectiveness to implementation. Behav. Res. Ther. 2009; 47: 931-937.
33. Dannon PN, Iancu I, Lowengrub K, et al. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin. Neuropharmacol. 2007; 30: 326-334.
34. Frank J,. Lexicon of Psychiatry, Neurology and the Neurosciences. Lippincott Williams and Wilkins, Baltimore, MD, 2000.
35. Uhlenhuth EH, Matuzas W, Warner TD, Paine S, Lydiard RB, Pollack MH,. Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication. J. Clin. Psychopharmacol. 2000; 20: 622-627.
36. Uhlenhuth EH, Leon AC, Matuzas W,. Psychopathology of panic attacks in panic disorder. J. Affect. Disord. 2006; 92: 55-62.
37. Galaverni E, Pozo Navarro P, Bellini M,. A survey of panic symptoms in a primary care setting. Aten. Primaria 2005; 36: 312-316.
38. Deacon B, Lickel J, Abramowitz JS,. Medical utilization across the anxiety disorders. J. Anxiety Disord. 2008; 22: 344-350.